Floatz logo

Bet Bromodomain Inhibitor Zen-3694

Recurrent Ovarian High Grade Serous Adenocarcinoma

National Cancer Institute (NCI)Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

114 Active assets in the Recurrent Ovarian High Grade Serous Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
Olaparib
National Cancer Institute (NCI)
Phase 2/3BB
Letrozole
Memorial Sloan Kettering Cancer Center
Phase 3BB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

Bet Bromodomain Inhibitor Zen-3694 is also rated in:

Advanced Malignant Solid NeoplasmDormant
B
Indicative ·
62 / 100
View asset →
prostate cancerDormant
B
Indicative ·
60 / 100
View asset →
triple-negative breast carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →